Appendix 1. Antidiabetic drugs of interest for the study, as available in Italy during the observation period. (DOC 57 kb
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Trend analysis of the proportion of patients treated with antibiotics by indication and type of mole...
Appendix 2. Exposure categories for the description of antidiabetic drug treatment received by new i...
Figure S1. Age-sex standardized prevalence of use of incretin-based medicines among antidiabetic dru...
Figure S2. Age-sex standardized incidence of use of incretin-based medicines among antidiabetic drug...
Figure S6. Incidence of use of incretin-based medicines per geographic area. (PDF 7 kb
Table S2a and S2b. Percentage of new users of GLP1 analogues by first active substance received. (DO...
Figure S5. Prevalence of use of incretin-based medicines per geographic area. (ZIP 7 kb
Figure S3. Prevalence of use of incretin-based medicines by age and gender. (ZIP 58 kb
Figure S4. Incidence of use of incretin-based medicines by age and gender. (ZIP 58 kb
Map of the study area (Figure S1); review of reference guidelines on diabetes management available i...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Abstract Background The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 i...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Trend analysis of the proportion of patients treated with antibiotics by indication and type of mole...
Appendix 2. Exposure categories for the description of antidiabetic drug treatment received by new i...
Figure S1. Age-sex standardized prevalence of use of incretin-based medicines among antidiabetic dru...
Figure S2. Age-sex standardized incidence of use of incretin-based medicines among antidiabetic drug...
Figure S6. Incidence of use of incretin-based medicines per geographic area. (PDF 7 kb
Table S2a and S2b. Percentage of new users of GLP1 analogues by first active substance received. (DO...
Figure S5. Prevalence of use of incretin-based medicines per geographic area. (ZIP 7 kb
Figure S3. Prevalence of use of incretin-based medicines by age and gender. (ZIP 58 kb
Figure S4. Incidence of use of incretin-based medicines by age and gender. (ZIP 58 kb
Map of the study area (Figure S1); review of reference guidelines on diabetes management available i...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Abstract Background The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 i...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Background: The incretin-based medicines GLP1 analogues (GLP1a) and dipeptidyl peptidase-4 inhibitor...
Trend analysis of the proportion of patients treated with antibiotics by indication and type of mole...